Down-regulation of central glucocorticoid receptor expression using antisense oligonucleotide technology
Endogenous glucocorticoids and serotonin have been implicated in the pathophysiology of depression, anxiety and schizophrenia. This thesis investigates the potential of downregulating expression of central Type II glucocorticoid receptors (GR) both in vitro and in vivo, with empirically-designed ant...
Main Author: | |
---|---|
Published: |
Aston University
2000
|
Subjects: | |
Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.341351 |
id |
ndltd-bl.uk-oai-ethos.bl.uk-341351 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-bl.uk-oai-ethos.bl.uk-3413512017-04-20T03:28:36ZDown-regulation of central glucocorticoid receptor expression using antisense oligonucleotide technologyIslam, Aminul2000Endogenous glucocorticoids and serotonin have been implicated in the pathophysiology of depression, anxiety and schizophrenia. This thesis investigates the potential of downregulating expression of central Type II glucocorticoid receptors (GR) both in vitro and in vivo, with empirically-designed antisense oligodeoxynucleotides (ODN), to characterise GR modulation of 5-HT2A receptor expression using quantitative RT-PCR, Western blot analysis and radioligand binding. The functional consequence of GR downregulation is also determined by measuring 1-(2,5-dimethoxy 4-iodophenyl)-2-amino propane hydrochloride (DOI) mediated 5-HT2A receptor specific headshakes. Using a library of random antisense ODN probes, RNAse H accessibility mapping of T7-primed, in vitro transcribed GR mRNA revealed several potential cleavage sites and identified an optimally effect GR antisense ODN sequence of 21-mer length (GRAS5). In vitro efficacy studies using rat C6 glioma cells showed a 56% downregulation in GR mRNA levels and 80% downregulation in GR protein levels. In the same cells a 29% upregulation in 5-HT2A mRNA levels and 32% upregulation in 5-HT2A protein levels was revealed. This confirmed the optimal nature of the GRAS5 sequence to produce marked inhibition of GR gene expression, and also revealed GR modulation of the 50-HT2A receptor subtype in C6 glioma cells to be a tonic repression of receptor expression. The distribution of a fluorescently-labelled GRAS5 ODN was detected in diverse areas of the rat brain after single ICV administration, although this fluorescence signal was not sustained over a period of 5 days. However, fluorescently-labelled GRAS5 ODN, when formulated in polymer microspheres, showed diverse distribution in the brain which was maintained for 5 days following a single ICV administration. This produced no apparent neurotoxic effects on rat behaviour and hypothalamic-pituitary-adrenal (HPA) axis homeostasis.610PharmacyAston Universityhttp://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.341351http://publications.aston.ac.uk/12358/Electronic Thesis or Dissertation |
collection |
NDLTD |
sources |
NDLTD |
topic |
610 Pharmacy |
spellingShingle |
610 Pharmacy Islam, Aminul Down-regulation of central glucocorticoid receptor expression using antisense oligonucleotide technology |
description |
Endogenous glucocorticoids and serotonin have been implicated in the pathophysiology of depression, anxiety and schizophrenia. This thesis investigates the potential of downregulating expression of central Type II glucocorticoid receptors (GR) both in vitro and in vivo, with empirically-designed antisense oligodeoxynucleotides (ODN), to characterise GR modulation of 5-HT2A receptor expression using quantitative RT-PCR, Western blot analysis and radioligand binding. The functional consequence of GR downregulation is also determined by measuring 1-(2,5-dimethoxy 4-iodophenyl)-2-amino propane hydrochloride (DOI) mediated 5-HT2A receptor specific headshakes. Using a library of random antisense ODN probes, RNAse H accessibility mapping of T7-primed, in vitro transcribed GR mRNA revealed several potential cleavage sites and identified an optimally effect GR antisense ODN sequence of 21-mer length (GRAS5). In vitro efficacy studies using rat C6 glioma cells showed a 56% downregulation in GR mRNA levels and 80% downregulation in GR protein levels. In the same cells a 29% upregulation in 5-HT2A mRNA levels and 32% upregulation in 5-HT2A protein levels was revealed. This confirmed the optimal nature of the GRAS5 sequence to produce marked inhibition of GR gene expression, and also revealed GR modulation of the 50-HT2A receptor subtype in C6 glioma cells to be a tonic repression of receptor expression. The distribution of a fluorescently-labelled GRAS5 ODN was detected in diverse areas of the rat brain after single ICV administration, although this fluorescence signal was not sustained over a period of 5 days. However, fluorescently-labelled GRAS5 ODN, when formulated in polymer microspheres, showed diverse distribution in the brain which was maintained for 5 days following a single ICV administration. This produced no apparent neurotoxic effects on rat behaviour and hypothalamic-pituitary-adrenal (HPA) axis homeostasis. |
author |
Islam, Aminul |
author_facet |
Islam, Aminul |
author_sort |
Islam, Aminul |
title |
Down-regulation of central glucocorticoid receptor expression using antisense oligonucleotide technology |
title_short |
Down-regulation of central glucocorticoid receptor expression using antisense oligonucleotide technology |
title_full |
Down-regulation of central glucocorticoid receptor expression using antisense oligonucleotide technology |
title_fullStr |
Down-regulation of central glucocorticoid receptor expression using antisense oligonucleotide technology |
title_full_unstemmed |
Down-regulation of central glucocorticoid receptor expression using antisense oligonucleotide technology |
title_sort |
down-regulation of central glucocorticoid receptor expression using antisense oligonucleotide technology |
publisher |
Aston University |
publishDate |
2000 |
url |
http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.341351 |
work_keys_str_mv |
AT islamaminul downregulationofcentralglucocorticoidreceptorexpressionusingantisenseoligonucleotidetechnology |
_version_ |
1718440947073679360 |